<DOC>
	<DOCNO>NCT02377791</DOCNO>
	<brief_summary>Tacrolimus drug use commonly kidney transplant patient prevent graft rejection . Tacrolimus act narrow range blood optimum activity . If level high , risk kidney injury , whereas , level low high risk rejection graft loss . Genetic difference gene cod enzyme cytochrome P450 ( CYP3A5 ) , responsible break active tacrolimus contribute variation blood level tacrolimus among different individual take dose drug . Certain genetic type lead low concentration , whereas certain genetic type lead high level . The proportion individual different type genetic variation differ among different ethnic population . Limited data available Thai subject risk certain type genetic variation risk rejection . This study aim compare effect different type CYP3A5 gene variation Tacrolimus drug level risk acute rejection Thais .</brief_summary>
	<brief_title>Impact CYP3A5 Gene Polymorphisms Tacrolimus Concentrations Outcomes Thai Transplant Recipients</brief_title>
	<detailed_description>Rationale important theory hypothesis : Tacrolimus , potent calcineurin inhibitor , commonly use kidney transplant patient worldwide . Tacrolimus narrow therapeutic index . Overdosing increase risk dose-related adverse drug reaction infection , whereas underdosing increase risk rejection graft loss . In addition , achieve therapeutic tacrolimus level complicate high intra- inter-individual pharmacokinetic variability drug . Though , source pharmacokinetic variability tacrolimus fully understood . It known inter-individual variation metabolism tacrolimus least partly due difference expression cytochrome P450 ( CYP ) 3A5 enzyme , one key proteins involve tacrolimus systematic clearance . Mutations due single nucleotide polymorphism ( SNP ) gene encode CYP 3A5 demonstrate affect expression . Among CYP3A5 allele , CYP3A5*1 find main allele associate CYP 3A5 expression , whereas mutant allele CYP3A5*3 prevent expression enzyme . Several study show mutation affect dose tacrolimus . The frequency CYP3A5 SNP vary among different ethnic population . In small study Thais , frequency , CYP3A5*1/*1 genotyping identify 20.6 % patient , CYP3A5*1/*3 35.3 % CYP3A5*3/*3 44.1 % . To best knowledge , previous study impact CYP 3A5 genetic polymorphism tacrolimus blood concentration acute rejection rate early stage post-transplantation Thai kidney transplant recipient . Evaluation CYP3A5 polymorphism may helpful determine appropriate start dose , timely achieve target level , improve outcome tacrolimus-based therapy group patient . Therefore , determine impact CYP 3A5 genetic polymorphism tacrolimus trough blood concentration first post-operative week acute rejection rate 3-month post-transplantation compare CYP3A5 expressers ( CYP3A5*1 homozygotes heterozygote ) CYP3A5 non-expressers ( CYP3A5*3 homozygotes ) . Methods : Study population : This retrospective analytical study perform Ramathibodi hospital , Bangkok , Thailand . Thai recipients underwent kidney transplantation January 2011 December 2013 . Data collection : Demographics clinical data gather medical file record . Blood sample collect determination genotype CYP3A5 , metabolic enzyme transport protein respect correspond effect pharmacokinetics tacrolimus . Approval study obtain ethic committee Ramathibodi hospital , Faculty Medicine , Mahidol University . Number sample : According study Sang-Il Min , et al , effect CYP3A5*1 allele early acute rejection graft function patient kidney transplant receive tacrolimus . CYP3A5 expressers ( n=29 ) mean trough concentration dose ratio 127.09 ± 69.40 ng/mL/mg/kg . While CYP3A5 non-expressers ( n=33 ) mean trough concentration dose ratio 220.99 ± 108.95 ng/mL/mg/kg day 10 kidney transplantation . The sample size estimate use formula : n/group=2 ( Zα + Zβ ) 2σ2/ ( µ1-µ2 ) 2 Given dose adjust Co Tac among expressor µ1= 127.09±69.40 different least 25 % would clinical significant absolute different 30 . Calculated sample size least 85 patient per group total subject would least 170 patient . Ref . Transplantation 2010 ; 90 : 1394-1400 Statistical analysis : Differences genotype assess use SPSS version 17.0 software chi square Mann-Whitney U test .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . Kidney transplantation January 2011 December 2013 2 . Received two divided daily dos tacrolimus initial regimen prevention allograft rejection 3 . Informed consent 1. multiple organ transplantation 2. hyperacute rejection 3. nonfunctioning graft , 4 . ABO incompatible kidney transplantation 5. severe liver function hypoalbuminemia ( serum albumin &lt; 3 g/dl ) 6. severe gastrointestinal disorder could interfere ability absorb oral medication 7. patient whose record data incomplete ; 8 . Receiving medication significantly interfere tacrolimus pharmacokinetics ( except methylprednisolone prednisolone )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>tacrolimus</keyword>
	<keyword>Cytochrome P-450 CYP3A</keyword>
	<keyword>Kidney transplant</keyword>
	<keyword>FK506</keyword>
	<keyword>Prograf</keyword>
	<keyword>Rejection</keyword>
	<keyword>Gene Polymorphism</keyword>
</DOC>